The Sunshine Hormone You Are Probably Deficient In
Vitamin D is not actually a vitamin. It is a secosteroid hormone with receptors on virtually every cell in the human body. It regulates over 200 genes involved in immune function, bone metabolism, cardiovascular health, mood regulation, insulin sensitivity, cancer prevention, and reproductive function. Calling it a vitamin understates its biological significance. It is one of the most critical signaling molecules in human physiology.
Over 40 percent of American adults are deficient, defined as below 30 ng/mL by conventional standards. Among African Americans, the deficiency rate exceeds 80 percent due to melanin's reduction of UV-mediated synthesis. Among adults over 65, deficiency affects approximately 70 percent. These are not niche populations. This is a deficiency affecting the majority of specific demographic groups and a substantial plurality of the general population.
Geography compounds the problem. Anyone living above the 37th parallel, roughly north of Los Angeles, cannot produce adequate vitamin D from sunlight for approximately 6 months of the year due to the angle of UVB radiation. Sunscreen with SPF 30 blocks approximately 97 percent of vitamin D synthesis. Indoor lifestyles and office work eliminate sun exposure during peak UVB hours. Modern humans are profoundly deficient in a hormone their bodies evolved to produce abundantly through daily sun exposure.
The clinical consequences are wide-ranging: autoimmune disease risk increases significantly below 40 ng/mL, depression prevalence increases, bone density declines, cardiovascular risk elevates, immune function deteriorates, and insulin resistance worsens. Yet vitamin D testing is not part of the standard annual physical at most practices, and when it is ordered, the target is the bare minimum to prevent rickets rather than the level required for systemic protection.
Why 30 ng/mL Is Not Enough
The conventional reference range for vitamin D, 30 to 100 ng/mL, has a floor set to prevent rickets and osteomalacia. These are severe bone diseases caused by profound vitamin D deficiency. Preventing rickets is a low bar. It does not represent optimal health. It represents the absence of a specific deficiency disease.
Research consistently demonstrates that the biological effects of vitamin D are dose-dependent, with meaningful clinical thresholds well above 30. Immune optimization, the activation of antimicrobial peptides, natural killer cell function, and T-cell modulation, requires levels above 40 to 50 ng/mL. Studies during the COVID-19 pandemic demonstrated significantly reduced severity and mortality in patients with levels above 50.
Autoimmune disease risk increases substantially below 40 ng/mL. A landmark study following over 25,000 participants demonstrated that vitamin D supplementation achieving levels above 50 reduced autoimmune disease incidence by 22 percent over five years. Depression prevalence correlates inversely with vitamin D levels, with levels below 40 showing significantly higher rates. Insulin sensitivity improves as levels rise from 30 to 60.
The optimal functional range, supported by the preponderance of clinical evidence, is 50 to 80 ng/mL. Levels between 30 and 50, labeled normal by conventional standards, represent a suboptimal zone where basic skeletal function is maintained but immune, metabolic, neurological, and cardiovascular benefits are not fully realized. The difference between 32 and 65 is not academic. It is the difference between preventing rickets and preventing chronic disease.
The Cofactor Problem: Magnesium, K2, Boron
Vitamin D supplementation without cofactor support is like putting gasoline in a car without spark plugs. The fuel is present but the engine cannot use it. This is why millions of Americans take vitamin D supplements and see minimal improvement in their levels or their symptoms.
Magnesium is the most critical cofactor. Vitamin D undergoes two hydroxylation steps to become its active form, calcitriol: first in the liver to become 25-OH vitamin D, then in the kidneys to become 1,25-dihydroxy vitamin D. Both steps require magnesium-dependent enzymes. If you are magnesium deficient, and an estimated 50 to 80 percent of Americans are, supplemental vitamin D cannot be activated regardless of dose. You are swallowing it but your body cannot convert it to the form that works.
Vitamin K2, specifically the MK-7 form, directs calcium metabolism in coordination with vitamin D. Vitamin D increases calcium absorption from the gut. K2 ensures that absorbed calcium is deposited into bones and teeth rather than into arterial walls and soft tissue. Supplementing vitamin D without K2 can contribute to vascular calcification, particularly at higher doses. The combination is essential, not optional.
Boron, a trace mineral often overlooked, supports vitamin D metabolism by extending its half-life and reducing its urinary excretion. Zinc supports vitamin D receptor function, improving cellular response to circulating vitamin D. Without this cofactor network, vitamin D supplementation is incomplete at best and potentially counterproductive. At Kure Health, the VITAL Index tests vitamin D alongside all relevant cofactors to ensure that optimization is systemic, not piecemeal.
Genetic Variants and VDR Polymorphisms
Vitamin D receptor polymorphisms, known as VDR variants, affect how efficiently your cells respond to vitamin D. The VDR gene encodes the nuclear receptor that vitamin D activates to produce its biological effects. Variants in this gene, present in significant portions of the population, can meaningfully alter vitamin D's effectiveness even at adequate blood levels.
The most studied VDR polymorphisms include FokI, BsmI, ApaI, and TaqI. The FokI variant affects the structure of the VDR protein itself, potentially altering its binding affinity to vitamin D and its interaction with gene promoter regions. Individuals carrying certain FokI variants may require higher circulating vitamin D levels to achieve the same cellular effects as those with the wild-type receptor.
This explains a common clinical frustration: two patients with identical vitamin D levels of 55 ng/mL can have dramatically different clinical responses. One feels markedly better with improved immune function and mood. The other notices minimal change. The difference is receptor efficiency. The patient with reduced VDR function may need levels of 70 to 80 ng/mL to achieve the same intracellular effects that the other achieves at 50.
AgeCode genetic analysis within the VITAL Index identifies VDR polymorphisms alongside other nutrient processing variants. This allows vitamin D optimization to be truly individualized: not just reaching a population-derived target level but achieving the intracellular effect that your specific genetic architecture requires. For patients with VDR variants, higher doses, liquid or sublingual delivery for improved absorption, and more aggressive cofactor support may be necessary.
Optimal Supplementation Strategy
Effective vitamin D optimization is a system, not a pill. The protocol begins with testing: 25-OH vitamin D establishes baseline levels. RBC magnesium confirms cofactor readiness. Calcium and PTH ensure that supplementation will not create calcium metabolism imbalance. AgeCode genetic analysis identifies VDR variants that affect dosing requirements.
Initial repletion for patients with levels below 30 ng/mL typically requires 10,000 IU of vitamin D3 daily for 8 to 12 weeks. For patients between 30 and 50, 5,000 to 8,000 IU daily is the standard repletion dose. Vitamin D3, cholecalciferol, is preferred over D2, ergocalciferol, which is less effective at raising and maintaining serum levels. Liquid or softgel forms are preferred over tablets for superior absorption. All doses should be taken with a fat-containing meal since vitamin D is fat-soluble.
Concurrent cofactor supplementation is non-negotiable: magnesium glycinate at 400 to 600 mg daily for enzymatic activation, vitamin K2 as MK-7 at 100 to 200 mcg daily for calcium direction, zinc at 25 to 30 mg daily for receptor function, and boron at 3 to 6 mg daily for half-life extension. For patients with documented gut absorption impairment from SIBO, IBD, celiac, or other gastrointestinal conditions, sublingual drops or intramuscular injection may be necessary to bypass the compromised GI tract.
Monitoring requires retesting every 8 to 12 weeks during the optimization phase to calibrate dosing. The goal is sustained levels of 50 to 80 ng/mL across seasons. Winter months in northern latitudes may require dose increases. Once stable, annual or biannual monitoring maintains optimal levels. This is the Signal-Based Medicine approach to nutrient optimization: test, identify cofactor status and genetic variants, supplement precisely, monitor, adjust. Not guess, swallow a generic dose, and hope.
